Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
M SaletuB Saletu

Abstract

Restless legs syndrome (RLS) - a common sensorimotor disorder - and periodic limb movement disorder (PLMD) are currently treated with substances of four classes: dopaminergic agents, which are considered the drugs of choice, benzodiazepines, opioids and anticonvulsants. As their effects on sleep variables differ considerably, the aim of the present placebo-controlled sleep laboratory study was to measure the acute effects of 1 mg clonazepam on objective and subjective sleep and awakening quality in ten RLS and 16 PLMD patients, utilizing polysomnography (PSG) and psychometry. Descriptive data analysis demonstrated at the confirmatory level concerning three target variables that - as compared with placebo - clonazepam significantly improved objective sleep efficiency and subjective sleep quality in both patient groups, but failed to reduce the index PLM/h of sleep. At the descriptive level, in PLMD clonazepam improved PLM during time in bed, REM and wakefulness and showed more significant changes in various sleep and awakening measures than in RLS patients, though there were no significant inter-group differences. In conclusion, in both PLMD and RLS clonazepam exhibited acute therapeutic efficacy regarding insomnia, which is qui...Continue Reading

References

Mar 17, 1979·British Medical Journal·W B Matthews
Jan 1, 1992·The Journal of Neuropsychiatry and Clinical Neurosciences·R C Smith
Dec 1, 1991·Aging : Clinical and Experimental Research·M H Bonnet, D L Arand
Dec 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·R Peled, P Lavie
Jul 1, 1985·Journal of Gerontology·S Ancoli-IsraelO J Kaplan
Jan 1, 1983·European Journal of Clinical Pharmacology·O LundvallR Holm
Jun 1, 1984·Acta Neurologica Scandinavica·P MontagnaE Lugaresi
Feb 11, 1984·British Medical Journal·W TelstadR Nyberg-Hansen
Feb 1, 1980·Archives of Neurology·M A Oshtory, N Vijayan
Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·A S Walters
Apr 1, 1997·Clinical Neuropharmacology·C H Adler
Jul 1, 1997·The International Journal of Eating Disorders·C S RandA J Stunkard
Aug 1, 1997·Home Healthcare Nurse·M A Boucher
Aug 18, 2004·Sleep Medicine Reviews·R M Rijsman, A W de Weerd

❮ Previous
Next ❯

Citations

May 16, 2009·Journal of Neurology·Claudia TrenkwalderJuliane Winkelmann
Nov 1, 2011·Sleep & Breathing = Schlaf & Atmung·Paul YehJohn W Tsuang
Jan 5, 2008·Current Treatment Options in Neurology·Janet C Lam, Thornton B A Mason
Jul 30, 2011·Current Treatment Options in Neurology·Mary Ann Thenganatt, Steven J Frucht
Jun 7, 2005·Primary Care·Ilia Itin, Cynthia L Comella
May 3, 2007·Journal of Palliative Medicine·Lauren B ElmanLeo McCluskey
Dec 13, 2005·Clinical Neuropharmacology·Sung-Wan KimJin-Sang Yoon
May 14, 2008·Southern Medical Journal·Eric Ball, Christine K Caivano
Jan 25, 2005·Nephrology·Roselyne M RijsmanJohan B Rosman
Sep 22, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L VignatelliUNKNOWN EFNS Task Force
Mar 26, 2013·Postgraduate Medical Journal·Kavitha Nagandla, Somsubhra De
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Gulcin Benbir, Christian Guilleminault
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Philip M Becker
Mar 25, 2008·Therapeutics and Clinical Risk Management·Paul E Cotter, Shaun T O'Keeffe
May 10, 2012·Therapeutics and Clinical Risk Management·Sheila Sivam, Brendon J Yee
Apr 20, 2006·Drugs·Miklos Z MolnarIstvan Mucsi
Jan 21, 2004·CNS Drugs·Svenja Happe, Claudia Trenkwalder
Jul 17, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Lawrence T ParkTheodore A Stern
Dec 24, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Cynthia L Comella
Jul 29, 2008·Revue neurologique·E KarroumI Arnulf
Aug 9, 2005·Expert Opinion on Emerging Drugs·Stephany Fulda, Thomas C Wetter
Apr 1, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jiro TakakiTomifusa Kuboki
Jul 15, 2005·Journal of Paediatrics and Child Health·Thomas A CampbellArthur Teng
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Thomas C WetterIlonka Eisensehr
Apr 2, 2002·Expert Opinion on Investigational Drugs·Björn Wito Walther
May 31, 2015·Zeitschrift für Gerontologie und Geriatrie·H Frohnhofen, J Schlitzer
May 17, 2015·Sleep Medicine·Subhashie Wijemanne, Joseph Jankovic
Aug 11, 2006·Journal of the Neurological Sciences·Takashi NomuraKenji Nakashima
Oct 6, 2016·CNS Spectrums·Zeyad T SahliFrank I Tarazi
Apr 25, 2012·Journal of the American Psychiatric Nurses Association·Norma G Cuellar
Mar 26, 2015·Arquivos de neuro-psiquiatria·Alan Christmann FröhlichWalter André dos Santos Moraes
Dec 16, 2006·Nephrology News & Issues
Jun 22, 2012·Annals of Neurology·Mauro ManconiLuigi Ferini-Strambi
Jun 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Isaac ShpirerJose Martin Rabey
Aug 18, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Melody Ryan, John T Slevin
Feb 8, 2011·Orvosi hetilap·Anett LindnerMiklós Zsolt Molnár
Oct 13, 2009·Journal of Internal Medicine·Karl Ekbom, J Ulfberg
Jun 10, 2010·Nature Reviews. Neurology·Claudia Trenkwalder, Walter Paulus
Dec 3, 2013·Der Anaesthesist·F BartelkeW Kämmerer
Jul 19, 2003·Current Opinion in Neurology·Pinky Agarwal, Steven J Frucht

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.